Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Gemcitabine, and Doxorubicin in Renal Medullary Carcinoma
NCT03587662Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2018
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in renal medullary carcinoma (RMC), renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2018; status: completed.
02
Drugs
ixazomib
03
Conditions
renal medullary carcinoma (RMC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03587662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587662.